Skip to main content
Pangen Biotech Inc. logo

Pangen Biotech Inc. — Investor Relations & Filings

Ticker · 222110 ISIN · KR7222110009 KO Manufacturing
Open in API
Filings indexed 333 across all filing types
Latest filing 2026-03-09 Director's Dealing
Country KR South Korea
Listing KO 222110

About Pangen Biotech Inc.

https://pangen.com/layout/eng/home.php

Pangen Biotech Inc. is a biotechnology company specializing in the research, development, and manufacturing of biopharmaceuticals. The company utilizes its proprietary platform technologies, particularly those based on Chinese Hamster Ovary (CHO) cell lines, for the production of complex protein therapeutics. Its primary business activities include the development of a pipeline of biosimilar products, such as Erythropoietin (EPO) and Aflibercept. In addition to its own product pipeline, Pangen Biotech offers Contract Development and Manufacturing Organization (CDMO) services, providing expertise in cell line development and biopharmaceutical production to other firms. The company also supplies reagents and kits for research applications.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a Korean regulatory filing titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on the status of ownership of specific securities by executives and major shareholders). This is a standard disclosure form required by the Financial Supervisory Service (FSS) in South Korea when a director or major shareholder changes their shareholding position (in this case, a gift of shares). This falls under the category of 'Director's Dealing' (DIRS) as it reports personal share transactions by a company director.
2026-03-09 Korean
감사보고서제출
Audit Report / Information Classification · 98% confidence The document is a regulatory filing titled '감사보고서 제출' (Submission of Audit Report) from the company Pangen. It provides the audit opinion (unqualified/proper), key financial data (assets, liabilities, revenue, profit), and the name of the auditor (Seonghyun Accounting Corp). While it contains financial data, it is a standard regulatory disclosure form used in the Korean market to announce the receipt and submission of the audit report to the regulator, rather than the full annual report document itself. Therefore, it is classified as an Audit Report / Information document. FY 2025
2026-03-05 Korean
임원ㆍ주요주주특정증권등거래계획보고서
Director's Dealing Classification · 98% confidence The document is a 'Report on Trading Plan for Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주특정증권등거래계획보고서) filed with the Korean regulatory authorities (Financial Supervisory Service/Korea Exchange). This document outlines a planned transaction (over-the-counter purchase) of shares by a major shareholder (Huons Co., Ltd.) in the issuing company (Pangen Co., Ltd.). Since this is a regulatory filing regarding share transactions and ownership plans that does not fit into specific categories like 'Director's Dealing' (which usually refers to completed trades) or 'Major Shareholding Notification' (which is for crossing thresholds), it falls under the general regulatory filing category.
2026-02-13 Korean
임원ㆍ주요주주특정증권등거래계획보고서
Director's Dealing Classification · 98% confidence The document is a 'Report on Trading Plan for Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 거래계획보고서) filed with the Korean Financial Supervisory Service (FSS) and Korea Exchange. This document details a planned sale of shares by a major shareholder (Hwail Pharmaceutical) in a listed company (Pangen). While it involves share transactions, it is a formal regulatory filing regarding future trading plans rather than a simple 'Director's Dealing' (which usually reports past trades) or a 'Transaction in Own Shares' (which refers to company buybacks). Given the specific regulatory nature of this filing in the Korean market, it falls under the 'Regulatory Filings' category.
2026-02-13 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Management Reports Classification · 95% confidence The document is a regulatory filing from a Korean company (Pangen) announcing a significant change in financial results (revenue or profit structure change of 30% or more). This is a standard regulatory disclosure requirement in the Korean market (KRX) for preliminary financial results. Since it provides the initial announcement of financial performance figures (revenue, operating profit, net income) before the final audited report, it is classified as an Earnings Release (ER).
2026-02-03 Korean
임원ㆍ주요주주특정증권등거래계획보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Trading Plan for Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 거래계획보고서) filed with the Financial Supervisory Service (FSS) and Korea Exchange. This document details a planned transaction (a gift of shares) by an executive (Yoon Sung-tae) of Pangen Co., Ltd. In the context of financial filings, reports regarding insider trading plans or actual transactions by directors and executives are classified as 'Director's Dealing' (DIRS).
2026-01-27 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.